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Background: Real-world evidence lacks for clinical effectiveness and clinical toxicity associated with platinum-based
doublets in the first-line setting for advanced non-squamous non-small cell lung cancer (advNS-NSCLC) in Chinese
patients.
Methods: Patients receiving first-line chemotherapy for advNS-NSCLC in four Chinese tertiary care hospitals from
2007 to 2012 were retrospectively identified for chart review. Propensity score methods created best matched pairs
for platinum/pemetrexed versus other platinum-based doublets for head-to-head comparisons of early treatment
discontinuation (completed treatment cycles <4), treatment failure (progressive disease or early treatment
discontinuation), and adverse events (AE). Conventional multiple logistic regression analyses were also performed
to confirm the impact of the studied platinum-based doublets on early treatment discontinuation, treatment failure,
and hematological AE using vinorelbine/platinum as reference.
Results: 1,846 patients were included to create propensity score matched treatment groups for platinum/pemetrexed
versus docetaxel (95 pairs), paclitaxel (118 pairs), gemcitabine (199 pairs), and vinorelbine (72 pairs)-contained doublet,
respectively. Platinum/pemetrexed was associated with significantly lower risks of early treatment discontinuation
(odds ratio (OR) ranged from 0.239, p = 0.001 relative to platinum/docetaxel to 0.389, p = 0.003 relative to
platinum/paclitaxel) and treatment failure (OR ranged from 0.257, p < 0.001 relative to platinum/paclitaxel to
0.381, p < 0.001 relative to platinum/gemcitabine) than the other four studied doublets. Platinum/pemetrexed was also
associated with several significantly lower hematological AE rates, such as versus platinum/paclitaxel (any
hematological AE: OR 0.508, p = 0.032), platinum/gemcitabine (i.e., any hematological AE: OR 0.383, p < 0.001;
anemia: OR 0.357, p < 0.001; thrombocytopenia: OR 0.345, p < 0.001) or platinum/vinorelbine (i.e., neutropenia: OR
0.360, p = 0.046; anemia: OR 0.181, p = 0.014) in matched patients. Further conventional logistic regression analyses
indicated that pemetrexed/platinum was ranked lowest for the risks of early treatment discontinuation (OR 0.326,
p < 0.001), treatment failure (OR 0.460, p < 0.001), and any hematological AE (OR 0.329, p < 0.001).
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Conclusions: Pemetrexed plus platinum had significantly superior clinical effectiveness as compared to the other
platinum-based doublets with third-generation cytotoxic agents and was also associated with several lower
hematological toxicity rates than gemcitabine or vinorelbine-based doublet in the first-line setting for advNS-NSCLC in
Chinese patients.
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The incidence of lung cancer in China has doubled in the
past decade [1] likely in part due to the aging population,
poorly controlled cigarette smoking, and worsening air
pollution associated with industrialization [2,3]. Non-
small cell lung cancer (NSCLC) accounts for over 80% of
lung cancer cases in China [4]. Because of the challenges
associated with tumor early detection [5], more than half
of Chinese patients with lung cancer are diagnosed at an
advanced stage [6], which is not curable and is associated
with a 5-year survival rate of less than 10% [7]. Thus,
chemotherapy is the main therapeutic option to extend
survival and to improve the quality of life in Chinese pa-
tients with advanced lung cancer [8].
The role of tumor histology in predicting treatment re-
sponse to chemotherapy for advanced NSCLC was first
suggested by a retrospective analysis reporting that peme-
trexed was associated with superior effects than docetaxel
in the second-line setting for advanced non-squamous
NSCLC (advNS-NSCLC) [9]. Another retrospective ana-
lysis based on a phase III trial comparing cisplatin/peme-
trexed versus cisplatin/gemcitabine in the first-line setting
for advanced NSCLC also reported significantly better
treatment response associated with pemetrexed treatment
[10]. However, the superior treatment response associated
with pemetrexed treatment for advNS-NSCLC has neither
been confirmed in real-world study settings nor in pa-
tients of non-Caucasian race. In addition, to our know-
ledge, pemetrexed has never been compared with other
third-generation cytotoxic agents for clinical effectiveness
and clinical toxicity in the first-line setting for advNS-
NSCLC in Chinese patients. Thus, we conducted this
retrospective cohort study to assess clinical effectiveness
and clinical toxicity associated with platinum-based dou-
blets in the first-line setting for advNS-NSCLC to confirm
previously reported data demonstrating significantly im-
proved tumor response associated with pemetrexed treat-
ment in the second-line setting [11] and to provide
general additional clinic evidence to support treatment de-
cision making in the first-line setting for advNS-NSCLC.Methods
This retrospective cohort study selected two tertiary care
hospitals [Chinese Academy of Medical Sciences Tumor
Hospital (CAMSTH) and Xuanwu Hospital (XWH)] forcancer care in Beijing (the national capital city of China,
2012 gross domestic product (GDP) per capita US$
13,797) [12] and two tertiary care hospitals [Hunan
Province Tumor Hospital (HNPTH), and Xiangya Hospital
(XYH)] for cancer care in Changsha (the capital city of
Hunan province, an inland province in southeastern
China, 2012 GDP per capita US$ 5,304) (12) for case iden-
tification in order to create a study cohort reflecting the
overall current social economic and referral patterns of
lung cancer patients in China. This study was approved by
the ethics committees of CAMSTH, XWH, HNPTH, and
XYH, respectively.Patient identification
Data were obtained from electronic hospital admission
registry databases in the selected two tertiary care hospi-
tals located in Beijing (CAMSTH and XWH) and two ter-
tiary care hospitals located in Changsha (HNPTH and
XYH). The period for identifying eligible cases was set
from January 1, 2007 to December 31, 2012. However, the
searching time periods for CAMSTH and XYH started
from January 1, 2009 and January 1, 2010, respectively, be-
cause the electronic hospital admission registry database
did not contain data prior to these dates. Eligible cases
were required to have a confirmed diagnosis of non-
squamous non-small cell lung cancer, be diagnosed with
Stage IIIB-IV disease, and have been treated with first-line
platinum-based doublet therapy including pemetrexed
(approved for second-line therapy in 2005 and subse-
quently approved for first-line chemotherapy in 2008),
docetaxel, paclitaxel, gemcitabine, or vinorelbine. The
platinum agent was limited to cisplatin or carboplatin, the
two most frequently used platinum agents in the first-line
setting for advanced NSCLC in China [8]. To identify
eligible cases, the diagnostic fields of hospital admission
registry databases were searched using keywords including
“lung cancer”, “NSCLC”, “small cell lung cancer”, “non-
squamous NSCLC”, “adenocarcinoma”, “large-cell lung
cancer”, and “squamous NSCLC”. After exclusion of pa-
tients with a diagnosis of small cell lung cancer or
squamous lung cancer, the identified patients with non-
squamous NSCLC or histologically unclassified lung
cancer were linked with their latest hospital records to
confirm their tumor histology. Hospital records of the
patients with biopsy or cytology-confirmed non-squamous
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tumor stage less than stage IIIB and patients who did not
receive first-line chemotherapy for their advanced lung
cancer. Finally, patients who received any tyrosine kinase
inhibitor (TKI), epidermal growth factor receptor (EGFR)
monoclonal antibody, or anti-angiogenic therapy in the
first-line setting were excluded to control their confound-
ing effects on outcome measures.Data extraction
The follow-up time for data extraction in our study was
set from the admission date of the hospitalization ini-
tializing first-line chemotherapy to the discharge date
of hospitalization with the last administration of first-line
chemotherapy. The medical records associated with the
first hospitalization were reviewed to extract each eligible
patient’s baseline characteristics including demographics
(gender, age), medical insurance type, smoking status prior
to lung cancer diagnosis, Eastern Cooperative Oncology
Group (ECOG) performance status, baseline laboratory
blood testing for hemoglobin level, white blood cell
(WBC) count, neutrophil granulocytes count, and platelet
count prior to administration of chemotherapy regiments,
tumor stage, tumor histology, number of metastatic sites,
and metastasis locations. The prescription records asso-
ciated with identified hospitalizations were reviewed to
extract doses and administration schedules of chemo-
therapeutic agents. Medical records associated with
hospitalizations during follow-up and after the comple-
tion of first-line chemotherapy were reviewed to extract
tumor response information from each assessment re-
lated to first-line chemotherapy. The tumor response
assessment in the four participating hospitals was based
on the Response Evaluation Criteria in Solid Tumors
(RECIST) evaluation criteria [13]. Chemotherapy adverse
events (AE) report forms associated with each hospitaliza-
tion during follow-up were reviewed to extract the infor-
mation on the occurrences and severity of AEs. Common
Terminology Criteria for Adverse Events (CTCAE) 3.0
with modifications on anemia for Chinese patients [14]
was used to grade AEs in the four participating hospitals.
Hospital records for laboratory blood testing during
follow-up were reviewed to extract reported hemoglobin
level, WBC count, neutrophilic granulocyte count, and
platelet count as additional information to assess occur-
rences and severity of hematological AEs. Hospital medi-
cation prescription records during follow-up were also
reviewed to extract information on the usages of medi-
cations (granulocyte colony-stimulating factor, G-CSF;
erythropoietin, EPO; interleukin 11, IL-11; and throm-
bopoietin, TPO) and blood products (red blood cell and
platelet) used for preventing and treating hematological
AEs. Finally, hospital admission and discharge datesassociated with each hospitalization during follow-up
were collected to calculate the length of hospital stay.
Outcome measures
Tumor response and the occurrences of AEs associated
with studied platinum-based doublets were the primary
outcome measures in this study. Because complete first-
line chemotherapy usually requires 4 to 6 treatment cy-
cles, early treatment discontinuation was defined as
completed treatment cycles less than 4 in our study. The
latest tumor response assessment based on RECIST after
the completion of chemotherapy was used to determine
the treatment response associated with the five studied
platinum-based doublets. Our study also defined disease
control [complete response (CR), partial response (PR),
or stable disease (SD)] and treatment failure [progressive
disease (PD) or early treatment discontinuation] for the
comparisons of clinical effectiveness among the studied
doublets. The identified AEs associated with the studied
platinum-based doublets during follow-up were classi-
fied as hematological and non-hematological. In order to
reduce the risk of missing information on AE assessment,
the recorded hematological AEs in medical notes and the
hematological AEs identified from blood laboratory testing
records during follow-up were used to determine occur-
rence and severity of hematological AE associated with
studied platinum-based doublets. The assessment of non-
hematological AEs was only based on recorded AEs in
medical records associated with included hospitalizations.
The measured secondary outcomes in our study included
the number of completed treatment cycles and average
length of hospital stay per treatment cycle.
Data analysis
Descriptive statistical methods were used to summarize
patient baseline characteristics, selected platinum agent in
doublet, and hematological AE management associated
with five studied platinum-based doublets. One-way
ANOVA analyses and chi square tests were used to
examine the differences in patient baseline characteristics
across the five treatment groups. Propensity score methods
and conventional regression methods were used respect-
ively to assess early treatment discontinuation, tumor re-
sponse, disease control, treatment failure, and clinical
toxicity associated with the studied platinum-based dou-
blets. Propensity score methods created best matched pairs
on patient baseline characteristics, platinum agent used in
doublet, and hematological AE management for platinum
plus pemetrexed versus the other four platinum-based
doublets, respectively, using greedy approach [15] with
matching condition of propensity score difference between
matched pair less than 0.001. Paired t-test and McNemar’s
test were used to compare the matched treatment groups
to assess the balance of patient baseline characteristics and
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average length of hospital stay per treatment cycle, tumor
response based on RECIST evaluation criteria, early treat-
ment discontinuation, disease control, treatment failure,
and AEs associated with chemotherapy. Further multiple
logistic regression analyses with generalized estimating
equation adjusted imbalanced baseline variables (p < 0.5
after matching) in propensity score matched patients [16]
to confirm the head-to-head comparisons of early treat-
ment discontinuation, treatment failure, and hematological
AEs. Finally, our study used conventional multiple logistic
regression analyses to rank the impact of the five studied
doublets using vinorelbine/platinum as reference on the
risks of early treatment discontinuation, treatment failure,
and hematological AEs after the adjustment of patient
baseline characteristics, platinum agent used in doublet,
and hematological AE management. Statistical significance
in our study was defined as two-sided p value less than
0.05 and SAS 9.2 was used to perform the data analyses as
described above.
Results
The initial screening hospital admission registry databases
of the four selected hospitals identified 9,270 patients with
lung cancer. After excluding134 patients without tumor
histology information, 279 patients with tumor stage less
than IIIB, 181 patients with small cell lung cancer, 458 pa-
tients with squamous NSCLC, 314 patients with mixed
squamous and non-squamous NSCLC, 5,529 patients who
did not receive first-line treatment or started first-line
treatment in other hospitals, 368 patients receiving first-
line chemotherapy regimens other than the five studied
platinum-based doublets, 79 patients receiving TKI, EGFR
monoclonal antibody, or anti-angiogenic therapy in the
first-line setting, and 82 patients receiving platinum-based
doublets containing platinum agent that was not cisplatin
or carboplatin, there were a total of 1,846 eligible patients
included in the data analysis. The patient identification
flow charts in the four hospitals are illustrated in Figure 1.
Patient baseline characteristics, platinum agent in
doublet, and hematological AE management
Of the included 1,846 patients, 517 patients received plat-
inum/pemetrexed, 248 patients received platinum/do-
cetaxel, 322 patients received platinum/paclitaxel, 450
patients received platinum/gemcitabine, and 309 patients
received platinum/vinorelbine. Many patient baseline
characteristics did not vary substantially across the five
platinum-based doublets (Table 1). The identified base-
line characteristics with significant differences across
the five treatment groups included age (mean from 53.5
to 55.5 years, p = 0.019), body surface area (mean from
1.6 to 1.7 m2, p < 0.001), non-smoking prevalence rates
(from 43.2% to 56.3%, p = 0.003), distribution of publichealth insurance plan for urban (from 42.7% to 59.4%,
p < 0.001) and rural residents (from 17.2% to 40.8%, p <
0.001), distribution of ECOG performance status of 0
(from 19.4% to 39.8%, p < 0.001) and 1 (from 58.8% to
76.7%, p < 0.001), baseline hemoglobin (mean from
129.4 to 132.9 g/l, p = 0.043), and distributions of tumor
stage IV (from 80.4% to 92.5%, p < 0.001) and pleural
metastasis (from 11.3% to 24.8%, p < 0.001).
Comparisons of the distribution of selected platinum
agent contained in the studied doublets indicated that
cisplatin was used most often in patients receiving plat-
inum/vinorelbine (87.9%, p < 0.001) and carboplatin was
used most often in patients treated by platinum/doce-
taxel (55.3%, p < 0.001). Further comparisons of the dis-
tributions of medications and blood products used for
treating hematological AEs suggested that G-CSF was
the most frequently used medication (ranged from 33.3%
in patients receiving platinum/pemetrexed to 69.6% in
patients receiving platinum/vinorelbine, p < 0.001). The
uses of EPO (n = 18, 1.0%), IL-11 (n = 107, 5.8%), and
TPO (n = 31, 1.7%) in our study cohort were much less
prevalent than the use of G-CSF. Blood transfusion (n =
14, 0.9%) and platelet infusion (n = 9, 0.5%) was rarely
used in our study cohort. The distributions of selected
platinum agent in the studied doublets and hematological
AE-related treatments are also summarized in Table 1.
Head-to-head comparisons of clinical effectiveness and
clinical toxicity between the propensity score matched
treatment groups
Propensity score methods created 95 best matched pairs
for platinum/pemetrexed versus platinum/docetaxel, 118
best matched pairs for platinum/pemetrexed versus plat-
inum/paclitaxel, 199 best matched pairs for platinum/
pemetrexed versus platinum/gemcitabine, and 72 best
matched pairs for platinum/pemetrexed versus platinum/
vinorelbine for head-to-head comparisons of tumor re-
sponse and clinical toxicity.
Clinical effectiveness
The distribution of cisplatin and carboplatin were well
balanced in the created matched treatment groups for all
comparisons. The five studied platinum-based doublets in
the matched patients were administrated every three
weeks and the average dosages of the five cytotoxic agents
per treatment cycle in the matched patients were similar
to what were recommended in clinical guidelines. When
compared to other four studied doublets, platinum/peme-
trexed was associated with significantly more completed
treatment cycles (mean differences: 0.5 cycles for the com-
parison with platinum/docetaxel, p = 0.028 to 0.9 cycles
for the comparison with platinum/gemcitabine, p < 0.001)
and significantly lower early treatment discontinuation
rate (rate ratio (RR): 0.674 for the comparison with
Figure 1 Flow chart to identify eligible patients in the four participating tertiary care hospitals. Abbreviations: CAMSTH, Chinese Academy
of Medical Sciences Tumor Hospital; XWH, Xuanwu Hospital; HNPTH, Hunan Province Tumor Hospital; XYH, Xiangya Hospital; TKI, tyrosine kinase
inhibitor; EGFR, epidermal growth factor receptor.
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parison with platinum/paclitaxel, p = 0.022). Additionally,
platinum/pemetrexed was associated with significantly
shorter length of hospital stay per treatment cycle than
paclitaxel (10.4+/−6.1 days vs. 13.5+/−11.7 days, p = 0.011),
gemcitabine (10.9+/−6.0 days vs. 15.0+/−7.0 days, p < 0.001),
or vinorelbine-contained doublet (13.1+/−7.2 days vs.
16.9+/−8.5 days, p = 0.001).
Our study compared the distribution of tumor response
assessed by RECIST between platinum/pemetrexed and
the other four studied doublets after the completions of
treatment cycles (3.33 to 3.58 cycles for platinum/pemetrexed, 2.89 cycles for platinum/docetaxel, 2.93 cycles
for platinum/paclitaxel, 2.71 cycles for platinum/gemcita-
bine, 2.49 cycles for platinum/vinorelbine) in propensity
score matched patients. Our study didn’t identify any CR
associated with the five studied platinum-based doublets
in the propensity score matched patients. Comparisons of
the distributions of tumor response classified by RECIST
observed significantly higher rates of PR associated with
platinum/pemetrexed when compared with paclitaxel
(18.6% vs. 5.1%, RR 3.647, p = 0.002) or gemcitabine-
contained doublet (18.1% vs. 9.1%, RR 1.989, p = 0.007).
Platinum/pemetrexed was also associated with significantly
Table 1 Patient baseline characteristics, selection of the platinum agent, and hematological AE management of studied doublets
Platinum-based doublet Platinum/Pemetrexed Platinum/Docetaxel Platinum/Paclitaxel Platinum/Gemcitabine Platinum/Vinorelbine
Sample size 517 248 322 450 309 P value*
Variables N Mean/% STDEV N Mean/% STDEV N Mean/% STDEV N Mean/% STDEV N Mean/% STDEV
Demography
Age (years) 511 55.5 9.8 248 54.1 9.9 322 53.8 10.5 447 55.1 9.4 308 53.5 10.2 0.019
BMI 441 23.6 3.2 136 23.9 3.2 214 23.5 3.3 332 23.7 3.3 103 23.0 3.4 0.228
BSA (m2) 457 1.7 0.2 214 1.7 0.2 276 1.7 0.2 395 1.7 0.2 266 1.6 0.2 <0.001
Male (%) 303 58.6% — 166 66.9% — 194 60.3% — 296 65.8% — 187 60.5% — 0.074
Non-smoking (%) 291 56.3% — 107 43.2% — 173 53.7% — 211 46.9% — 159 51.5% — 0.003
Public health insurance plan (%)
Urban residents 307 59.4% — 132 53.2% — 166 51.6% — 231 51.3% — 132 42.7% — <0.001
Rural residents 89 17.2% — 65 26.2% — 76 23.6% — 108 24.0% — 126 40.8% — <0.001
ECOG performance status (%)
0 193 37.3% — 58 23.4% — 128 39.8% — 133 29.6% — 60 19.4% — <0.001
1 304 58.8% — 180 72.6% — 190 59.0% — 299 66.4% — 237 76.7% — <0.001
2 13 2.5% — 9 3.6% — 3 0.9% — 13 2.9% — 10 3.2% — 0.265
Baseline marrow function
Hemoglobin (g/l) 495 132.9 17.6 241 131.0 16.5 317 132.8 15.3 426 132.5 19.3 304 129.4 17.3 0.043
Neutrophilic granulocyte count ( ×109/l) 491 5.2 2.4 239 4.9 2.2 318 5.2 2.3 422 5.2 2.6 304 4.9 2.0 0.112
WBC ( ×109/l) 495 7.6 2.6 242 7.4 2.8 318 7.6 2.7 428 7.8 2.8 305 7.5 2.4 0.601
Platelet count ( ×1010/l) 493 24.9 8.0 241 25.6 9.4 317 25.9 8.6 424 25.0 25.8 304 24.8 8.2 0.213
Tumor stage and histology (%)
Stage 4 478 92.5% — 215 86.7% — 273 84.8% — 395 87.8% — 248 80.4% — <0.001
Adenocarcinoma type 512 99.0% — 241 97.2% — 313 97.2% — 440 97.8% — 307 99.3% — 0.272
Number of metastasis site (%)
1 250 48.4% — 107 43.2% — 143 44.4% — 100 22.2% — 153 49.7% — 0.513
2 123 23.8% — 49 19.8% — 70 21.7% — 211 46.9% — 66 21.2% — 0.758
3 or above 64 12.4% — 20 8.1% — 32 9.9% — 100 22.2% — 22 7.2% — 0.083
Location of metastasis (%)
Brain 84 16.3% — 49 19.8% — 58 18.0% — 68 15.1% — 42 13.7% — 0.289
Bone 200 38.7% — 87 35.1% — 98 30.4% — 162 36.0% — 109 35.3% — 0.199
Liver 48 9.3% — 23 9.3% — 29 9.0% — 32 7.1% — 24 7.8% — 0.729


















Table 1 Patient baseline characteristics, selection of the platinum agent, and hematological AE management of studied doublets (Continued)
Platinum agent used in doublet
Cisplatin 400 77.4% — 111 44.7% — 251 77.8% — 385 85.6% — 272 87.9% — <0.001
Carboplatin 117 22.6% — 137 55.3% — 71 22.2% — 65 14.4% — 37 12.1% — <0.001
Hematological AE management
G-CSF 172 33.3% — 108 43.5% — 167 51.9% — 209 46.4% — 215 69.6% — <0.001
EPO 5 1.0% — 1 0.3% — 0 0.0% — 9 2.0% — 3 1.0% — 0.066
IL-11 16 3.1% — 5 1.9% — 3 0.9% — 44 9.8% — 39 12.6% — <0.001
TPO 17 3.3% — 2 0.6% — 0 0.0% — 9 2.0% — 3 1.0% — 0.003
RBC 1 0.2% — 0 0.0% — 0 0.0% — 5 1.1% — 8 2.6% — <0.001
Platelet 1 0.2% — 1 0.3% — 0 0.0% — 3 0.7% — 4 1.3% — 0.148
AE, adverse event; STDEV, standard deviation; BMI, body mass index; BSA, body surface area; ECOG, Eastern Cooperative Oncology Group; WBC, white blood cell; G-CSF, granulocyte colony-stimulating factor; EPO, erythropoietin;
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1.518, p = 0.025) or gemcitabine-contained doublet (36.2%
vs. 26.1%, RR 1.387, p = 0.043). Thus, platinum/peme-
trexed was associated with significantly higher disease con-
trol rate (RR: 1.357, p = 0.029 for the comparison with
platinum/docetaxel to 2.222, p = 0.005 for the comparison
with platinum/vinorelbine) than the other four studied
doublets in propensity score matched patients (Figure 2).
However, no significant differences were identified for the
comparisons of PD between platinum/pemetrexed and the
other four studied doublets likely because of a large
proportion of patients who did not have tumor re-
sponse assessment information due to early treatment
discontinuation. When using treatment failure as the out-
come to assess clinical effectiveness, platinum/pemetrexed
was associated with significantly lower rate of treatment
failure (RR: 0.537, p = 0.005 for the comparison with plat-
inum/vinorelbine to 0.717, p = 0.029 for the comparison
with platinum/docetaxel) than the other four studied dou-
blets. The results of head-to-head comparisons of treat-
ment pattern and clinical effectiveness between propensity
score matched treatment groups are summarized in
Table 2. With further adjustment of imbalanced baseline
variables after propensity score matching, platinum/peme-
trexed was confirmed to have significantly lower risks of
early treatment discontinuation (odds ratio (OR): 0.239,
p = 0.001 for the comparison with platinum/docetaxel to
0.389, p = 0.003 for the comparison with platinum/pacli-
taxel) and treatment failure (OR: 0.257, p < 0.001 for the
comparison with platinum/paclitaxel to 0.381, p < 0.001
for the comparison with platinum/gemcitabine) than the
other four studied doublets (Table 3).Figure 2 Comparisons of disease control rate (partial response or sta
platinum/pemetrexed and the other four studied platinum-based douClinical toxicity
The distribution of hematological AEs associated with
platinum/pemetrexed was not significantly different from
platinum/docetaxel or platinum/paclitaxel. However, plat-
inum/pemetrexed was associated with significantly lower
rates of leukopenia (32.2% vs. 42.2%, RR 0.762, p = 0.041),
anemia (29.6% vs. 50.3%, RR 0.590, p < 0.001), and
thrombocytopenia (43.7% vs. 62.8%, RR 0.696, p < 0.001)
than platinum/gemcitabine and significantly lower rate of
neutropenia (16.7% vs. 31.9%, RR 0.522, p = 0.034) than
platinum/vinorelbine (Table 4). With further adjusting
imbalanced baseline variables after propensity score
matching, platinum/pemetrexed was confirmed to have
a comparable hematological toxicity profile as plat-
inum/docetaxel but significantly less hematological tox-
icity than paclitaxel (any hematological AE: OR 0.508,
p = 0.032), gemcitabine (anemia: OR 0.357, p < 0.001;
thrombocytopenia: OR 0.345, p < 0.001; any hematological
AE: OR 0.383, p < 0.001), or vinorelbine-contained doub-
let (neutropenia: OR 0.360, p = 0.046; anemia: OR 0.181,
p = 0.014) (Table 3).
Head-to-head comparisons of non-hematological AEs
between propensity score matched treatment groups fur-
ther observed that platinum/pemetrexed was associated
with significantly fewer patients experiencing alopecia
than docetaxel (3.2% vs. 15.8%, RR 0.200, p = 0.005), pacli-
taxel (0.8% vs. 6.8%, RR 0.125, p = 0.020), or gemcitabine-
contained doublet (1.0% vs. 9.0%, RR 0.111, p < 0.001).
Platinum/pemetrexed was also associated with less fatigue
than paclitaxel (8.5% vs. 22.9%, RR 0.370, p = 0.001),
gemcitabine (9.0% vs. 31.2%, RR 0.290, p < 0.001), or
vinorelbine-contained doublet (18.1% vs. 31.9%, RRble disease reported by tumor response assessment) between
blets in the propensity score matched patients.






Matched pairs 95 RR P value* 118 RR P value* 199
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PR 13 13.7% 13 13.7% 1.000 1.000 22 18.6% 6 5.1% 3.647 0.002 36
SD 44 46.3% 29 30.5% 1.518 0.025 45 38.1% 32 27.1% 1.406 0.074 72
PD 9 9.5% 13 13.7% 0.693 0.371 11 9.3% 21 17.8% 0.522 0.059 24






45 47.4% 62 65.3% 0.726 0.007 52 44.1% 71 60.2% 0.732 0.022 91
Tumor control 57 60.0% 42 44.2% 1.357 0.029 67 56.8% 38 32.2% 1.764 <0.001 108
Treatment
failure


















Table 2 Head-to-head comparisons of treatment pattern and tumor response between the propensity score matched treatment groups (Continued)
Comparison Platinum/Pemetrexed vs.Platinum/Gemcitabine Platinum/Pemetrexed vs. Platinum/Vinorelbine
Matched pairs 199 RR P value* 72 RR P value*
Measured














PR 18.1% 18 9.1% 1.989 0.007 16 22.2% 9 12.5% 1.776 0.108
SD 36.2% 52 26.1% 1.387 0.043 28 38.9% 18 25.0% 1.556 0.077
PD 12.1% 23 11.6% 1.043 0.879 7 9.7% 12 16.7% 0.581 0.197






45.7% 135 67.8% 0.674 <0.001 38 52.8% 55 76.4% 0.691 0.007
Tumor control 54.3% 70 35.2% 1.543 <0.001 44 61.1% 20 27.5% 2.222 0.005
Treatment
failure
45.7% 129 64.8% 0.705 <0.001 28 38.9% 45 72.5% 0.537 0.005



















Table 3 Comparing early treatment discontinuation, treatment failure, and hematological AEs between matched treatment groups after adjusting imbalanced
baseline variables






































0.239 0.106 0.536 0.001 0.389 0.210 0.722 0.003 0.340 0.215 0.538 <0.001 0.250 0.096 0.654 0.005
Treatment failure 0.377 0.189 0.750 0.006 0.257 0.134 0.493 <0.001 0.381 0.241 0.601 <0.001 0.265 0.109 0.647 0.004
Hematological AE
Neutropenia 2.140 0.738 6.205 0.161 0.695 0.352 1.372 0.295 1.300 0.789 2.143 0.304 0.360 0.132 0.981 0.046
Leukopenia 2.028 0.691 5.948 0.198 0.687 0.351 1.345 0.273 0.633 0.392 1.023 0.062 0.423 0.165 1.082 0.073
Anemia 0.905 0.404 2.026 0.808 0.618 0.326 1.174 0.142 0.357 0.221 0.576 <0.001 0.181 0.046 0.710 0.014
Thrombocytopenia 0.790 0.287 2.178 0.649 0.581 0.287 1.174 0.130 0.345 0.209 0.570 <0.001 1.105 0.413 2.960 0.842
Any hematological AE 0.687 0.327 1.442 0.321 0.508 0.274 0.943 0.032 0.383 0.229 0.642 <0.001 0.332 0.092 1.200 0.093
































Matched pairs 95 RR P value* 118 RR P value* 199 RR P value* 72 RR P value*
All grades AE N % N % N % N % N % N % N % N %
Hematological AE
Leukopenia 29 30.5% 27 28.4% 1.074 0.752 34 28.8% 39 33.1% 0.872 0.508 64 32.2% 84 42.2% 0.762 0.041 18 25.0% 27 37.5% 0.667 0.106
Neutropenia 24 25.3% 19 20.0% 1.263 0.336 29 24.6% 35 29.7% 0.829 0.396 63 31.7% 57 28.6% 1.105 0.540 12 16.7% 23 31.9% 0.522 0.034
Thrombocytopenia 24 25.3% 24 25.3% 1.000 1.000 32 27.1% 34 28.8% 0.941 0.773 59 29.6% 100 50.3% 0.590 <0.001 25 34.7% 26 36.1% 0.962 0.876
Anemia 34 35.8% 31 32.6% 1.097 0.647 46 39.0% 53 44.9% 0.868 0.370 87 43.7% 125 62.8% 0.696 <0.001 35 48.6% 46 63.9% 0.761 0.063
Any hematological AE 56 58.9% 58 61.1% 0.966 0.752 70 59.3% 80 67.8% 0.875 0.189 130 65.3% 163 81.9% 0.798 <0.001 47 65.3% 58 80.6% 0.810 0.056
Non-hematological AE 0.0% 0.0%
Alopecia 3 3.2% 15 15.8% 0.200 0.005 1 0.8% 8 6.8% 0.125 0.020 2 1.0% 18 9.0% 0.111 <0.001 0 0.0% 1 1.4% 0.000 1.000
Arthralgia 5 5.3% 4 4.2% 1.250 0.706 0 0.0% 0 0.0% — — 2 1.0% 8 4.0% 0.250 0.058 0 0.0% 0 0.0% — —
Cough 1 1.1% 2 2.1% 0.500 0.564 1 0.8% 1 0.8% 1.000 1.000 3 1.5% 12 6.0% 0.250 0.020 2 2.8% 1 1.4% 2.000 0.564
Dermatitis 0 0.0% 0 0.0% — — 0 0.0% 0 0.0% — — 0 0.0% 0 0.0% — — 0 0.0% 0 0.0% — —
Diarrhea 1 1.1% 2 2.1% 0.500 0.317 1 0.8% 0 0.0% — 1.000 3 1.5% 0 0.0% — 0.250 2 2.8% 3 4.2% 0.667 0.655
Dyspnea 1 1.1% 0 0.0% — 1.000 1 0.8% 0 0.0% — 1.000 3 1.5% 6 3.0% 0.500 0.317 1 1.4% 0 0.0% — 1.000
Edema 1 1.1% 0 0.0% — 1.000 1 0.8% 0 0.0% — 1.000 3 1.5% 1 0.5% 3.000 0.317 1 1.4% 0 0.0% — 1.000
Fatigue 11 11.6% 11 11.6% 1.000 1.000 10 8.5% 27 22.9% 0.370 0.001 18 9.0% 62 31.2% 0.290 <0.001 13 18.1% 23 31.9% 0.565 0.048
Nausea 63 66.3% 67 70.5% 0.940 0.527 78 66.1% 84 71.2% 0.929 0.446 134 67.3% 148 74.4% 0.905 0.122 53 73.6% 53 73.6% 1.000 1.000
Peripheral neuropathy 1 1.1% 3 3.2% 0.333 0.317 0 0.0% 5 4.2% 0.000 0.063 3 1.5% 2 1.0% 1.500 0.657 1 1.4% 2 2.8% 0.500 0.564
Rash 2 2.1% 0 0.0% — 0.500 2 1.7% 0 0.0% — 0.500 5 2.5% 5 2.5% 1.000 1.000 1 1.4% 0 0.0% — 1.000
Stomatitis 0 0.0% 0 0.0% — — 0 0.0% 0 0.0% — — 0 0.0% 1 0.5% 0.000 1.000 0 0.0% 2 2.8% 0.000 0.500
Vomiting 40 42.1% 47 49.5% 0.851 0.286 51 43.2% 52 44.1% 0.981 0.895 92 46.2% 94 47.2% 0.979 0.849 31 43.1% 37 51.4% 0.838 0.366
Weight loss 0 0.0% 1 1.1% 0.000 1.000 0 0.0% 0 0.0% — — 0 0.0% 0 0.0% — — 0 0.0% 0 0.0% — —
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http://www.biomedcentral.com/1471-2407/14/9400.565, p = 0.048). Finally, platinum/pemetrexed was as-
sociated with significantly lower rate of cough (1.5% vs.
6.0%, RR 0.250, p = 0.020) when compared with plat-
inum/gemcitabine. All other non-hematologic toxicities
were not significantly different (Table 4).
Multiple logistic regression analyses assessing the risks of
early treatment discontinuation, treatment failure, and
hematological AEs
1,691 patients with complete information on patient
baseline characteristics and hematological AE manage-
ment were included for the assessment on the risks of
early treatment discontinuation, treatment failure, and
hematological AEs associated with the five studied
platinum-based doublets. When platinum/vinorelbine
was used as the reference, platinum/pemetrexed was
associated with the lowest odds of early treatment dis-
continuation (OR 0.326, p < 0.001) (Figure 3a) and
treatment failure (OR 0.460, p < 0.001) (Figure 3b). The
only other doublet to differ significantly from platinum/
vinorelbine regarding risk of early treatment discontinu-
ation was the platinum/paclitaxel doublet (OR 0.567,
p = 0.006). Docetaxel, paclitaxel, or gemcitabine-contained
doublet did not differ significantly from platinum/vino-
relbine regarding the odds of treatment failure. When
compared to platinum/vinorelbine for the risks of hema-
tological AEs, pemetrexed, docetaxel, and paclitaxel-
contained doublets were associated with significantly
reduced odds of experiencing any hematological AEs
(OR ranged from 0.329 to 0.433, all p values <0.001)
(Figure 3c), leukopenia (OR ranged from 0.546 to
0.631, p values ranged from 0.005 to 0.024) (Figure 3d),
and anemia (OR ranged from 0.218 to 0.374, all p
values < 0.001) (Figure 3e). Additionally, platinum/gem-
citabine was associated with significantly reduced odds
of neutropenia (OR 0.636, p = 0.020) (Figure 3f ) but
significantly greater thrombocytopenia (OR 1.832, p =
0.003) (Figure 3g) when compared with platinum/vino-
relbine. Finally, pemetrexed (OR 0.602, p = 0.015) or
docetaxel-contained doublet (OR 0.544, p = 0.008) had
significantly lower odds of thrombocytopenia than plat-
inum/vinorelbine (Figure 3g).
Discussion
To our knowledge, our study is the first and the largest
real-world study evaluating platinum-based doublets with
pemetrexed and the other four third-generation doublets
frequently used in the first-line setting for advNS-NSCLC.
Our study used two statistical approaches, propensity
score methods, and conventional regression methods, to
compare clinical effectiveness and clinical toxicity associ-
ated with the studied five platinum-based doublets.
Pemetrexed-based doublet was confirmed to be associated
with significantly better tumor control than gemcitabine-based doublet when treating advNS-NSCLC in the first-
line setting. Our study also generated evidence indicating
that the pemetrexed treatment was associated with signifi-
cantly lower odds of treatment failure versus other plat-
inum doublets in the first-line setting for advNS-NSCLC.
Further clinical toxicity assessment suggested that peme-
trexed, docetaxel, and paclitaxel-contained doublets
had comparable toxicity profiles, but gemcitabine and
vinorelbine-contained doublets were significantly associ-
ated with greater toxicities than platinum/pemetrexed.
Additionally, our study observed a significantly lower rate
of early treatment discontinuation and shorter length of
hospital stay per treatment cycle associated with peme-
trexed treatment when compared with other doublets. It
is possible that this could be due to differences in ob-
served clinical effectiveness and clinical toxicity between
the studied doublets.
Because pemetrexed in combination with cisplatin or
carboplatin has been proven to yield efficacy results com-
parable with other platinum doublets in chemotherapy
naïve patients with advanced NSCLC [17,18], the observed
superior clinical effectiveness associated with pemetrexed
in our study may be explained by the potential impact of
tumor histology on the anti-cancer mechanisms of the
studied third-generation cytotoxic agents. Because doce-
taxel, paclitaxel, vinorelbine are mitotic inhibitors [19] and
gemcitabine is a nucleoside analog [20], these four cyto-
toxic agents target common elements directly related to
tumor cell replication and their anti-cancer activities are
less sensitive to tumor histology. Pemetrexed inhibits
three key enzymes in the folate metabolic pathway in
tumor cells [21] and its anti-cancer activities are sensitive
to expressions of enzymes in the folate metabolic pathway
[22]. The observed superior clinical effectiveness associ-
ated with pemetrexed treatment in our study may be the
result of highly prevalent adenocarcinoma histology
(98.1%) in our study cohort, a histological subtype which
expresses thymidylate synthase, one of the three key en-
zymes inhibited by pemetrexed [23]. In addition, the
tumor response associated with platinum/pemetrexed in
our study was increased by over half when compared with
platinum/gemcitabine. However, the effects associated
with pemetrexed treatment were only increased by about
10% for the same comparison in a Phase III trial mainly
consisting Caucasian patients [10]. We also noticed that
the treatment effectiveness associated with platinum/
pemetrexed was much better than what was observed in
PointBreak study [24], a phase III trial observing highly
comparable disease control rates between carboplatin/
pemetrexed and carboplatin/paclitaxel. We compared the
patient baseline characteristics between the two studies
and the differences in patient baseline characteristics may
explain the differences in clinical findings in these two
studies. First, the average age of patients in our study was
Figure 3 Ranking the five studied doublets for tumor response and hematological AEs in 1691 included patients. a. Early treatment
discontinuation. b. Treatment failure. c. Any hematological AE. d. Leukopenia. e. Anemia. f. Neutropenia. g. Thrombocytopenia. Abbreviations: AE,
adverse event; OR, odds ratio; G-CSF, granulocyte colony-stimulating factor; EPO, erythropoietin; IL-11, interleukin 11; ECOG, Eastern Cooperative
Oncology Group; TPO, thrombopoietin. Note: Only baseline variables with significant OR and the studied doublets were displayed in graphs.
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study and younger age was likely to increase sensitivity
of pemetrexed treatment [25]. Second, patients in our
study mainly received cisplatin as platinum agent in the
studied doublets and cisplatin-based chemotherapy has
been proven to produce a higher response rate than
carboplatin-based chemotherapy in a meta-analysis of
eight trials including 2948 patients [26]. Third, almost
all patients in our study cohort had adenocarcinoma
lung cancer, which has lower expression of thymidylatesynthase, a proven predictor for better response to
pemetrexed treatment [27]. Finally, Chinese ethnicity in
our study cohort could be another potential predictor
to pemetrexed treatment as our previous study [11]
also found much stronger response associated with
pemetrexed treatment in the second-line setting in
Chinese patients when compared to other studies mainly
including Caucasian patients. Thus, the observed superior
clinical effectiveness associated with pemetrexed treat-
ment in our study should be further evaluated for their
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using a better study design and the possible predictive
roles of age, platinum agent, thymidylate synthase, and
Chinese ethnicity for the treatment response to peme-
trexed in the first-line setting for advNS-NSCLC should
be further investigated to guide future clinical practices.
Our study found that pemetrexed and docetaxel-
contained doublets had comparable toxicity profiles. It
is possible that the toxicity associated with a platinum
agent could mask the differences in toxicity between
pemetrexed and docetaxel. The significantly more com-
pleted treatment cycles associated with pemetrexed-based
therapy may also have played a role in the toxicity com-
parison, as there is the chance of more occurrences of
AEs with longer treatment duration; however, this analysis
was not conducted in the current study. In our study,
treatment with G-CSF was highly prevalent in patients re-
ceiving all the doublets; however, about half of patients
used G-CSF with the paclitaxel and gemcitabine doublets,
nearly 70% with vinorelbine, and approximately one-third
with pemetrexed. Of note, neutropenia and leukopenia
were identified in less than one-third of the paclitaxel, gem-
citabine or vinorelbine patient cohorts. The rates of G-CSF
use and rates of neutropenia and leukopenia associated
with platinum/pemetrexed were comparable in our study;
therefore we assumed that it was unlikely that prophylaxis
treatment with G-CSF was applied to patients receiving
pemetrexed treatment. Adjusting hematological AE man-
agement, mainly through adjusting the use of G-CSF, was
crucial to control bias when assessing hematological tox-
icity and also treatment effectiveness in our study.
The evidence generated in our study has meaningful
implications for clinical practice and future research.
The superior clinical effectiveness associated with plat-
inum/pemetrexed in our study could be used to further
support the role of tumor histology in guiding individual-
ized chemotherapy in the first-line setting for advanced
NSCLC. Our study has also filled current evidence gap in
managing advNS-NSCLC as there is a lack of real-world
evidence comparing pemetrexed treatment with docetaxel,
paclitaxel, or vinorelbine doublets. The strong treatment
response associated with pemetrexed in our study further
supported the hypothesis regarding the possible predictive
role of Chinese ethnicity and future studies are needed to
confirm this hypothesis. Different from chemotherapy
care in high-income countries, chemotherapy care in
China is usually conducted in hospital settings to monitor
and manage chemotherapy toxicity. The reported shorter
length of hospital stay associated with pemetrexed treat-
ments is expected to reduce health resources utilization
and have a positive impact on patient quality of life. Thus,
any additional benefits associated with pemetrexed treat-
ment on health resource utilization and quality of life
should be further clarified as these two outcomes havebeen increasingly used to support both treatment and re-
imbursement decision makings. Finally, the observed
highly prevalent use of G-CSF in our study suggests that
prophylaxis treatment is common in real-world settings
and adjusting the use of G-CSF is needed to minimize bias
in assessing chemotherapy in real-world studies.
Our study has limitations commonly associated with
retrospective studies. Therefore, these study results should
be carefully interpreted. First, our study was unable to
identify tumor response assessment for some patients dur-
ing or after chemotherapy. The risk of PD associated with
platinum/pemetrexed, the doublet with the lowest rate of
early treatment discontinuation that was associated with
no tumor response assessment, might be overestimated
when compared with other platinum-based doublets. Sec-
ond, our study could have underestimated clinical toxicity
because of the lack of information on AEs that occurred
outside of the four participating hospitals. Third, our
study did not adjust prophylaxis treatment for non-
hematological AEs and the true differences in non-
hematological toxicity among the studied platinum-based
doublets were unlikely observed in our study. Fourth, the
study results are based on highly selected patients using
the propensity score methods, which limit the external
validity [28] of the findings, despite confirmation of in-
ternal validity by conventional regression methods. Also,
the multiplicity was not adjusted to control the type I
error of this study. Finally, our study was unable to collect
survival data to assess treatment effects associated with
the studied platinum-based doublets. The observed super-
ior clinical effectiveness associated with pemetrexed treat-
ment has to be carefully interpreted until the impact of
these treatment effects on overall survival is fully clarified.
Conclusions
This large real-world retrospective cohort study with Chinese
patients supports previous studies showing improved dis-
ease control associated with platinum-based pemetrexed
doublet when compared to platinum-based doublet with
gemcitabine in first-line setting for advNS-NSCLC. This
study also indicated that pemetrexed treatment was also
associated with lower risk of treatment failure compared
to the other third-general cytotoxic agents combined with
platinum treatment in the first-line setting for advNS-
NSCLC. The toxicity data suggest that pemetrexed, doce-
taxel, and paclitaxel-contained doublets had comparable
toxicity profiles, but may be less toxic than gemcitabine or
vinorelbine-contained doublet. Finally, pemetrexed treat-
ment was associated with the lowest risk of early treat-
ment discontinuation (versus all other doublets) and the
shortest length of hospital stay among the treatments
(versus paclitaxel, vinorelbine or gemcitabine doublets)
in the first-line setting for advNS-NSCLC likely because
of its superior effectiveness and less toxicity.
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